WST

HealthEquity, Inc. HQY reported adjusted earnings per share (EPS) of $1.24 for first-quarter fiscal 2027, surpassing the Zacks Consensus Estimate by 11.7%. The bottom line improved 28% on a year-over-year basis. GAAP EPS in the fiscal first quarter was 82 cents, up from the year-ago quarter’s EPS of 61 cents. Shares of HQY gained 1.04% in after-market trading following the earnings call. In the fiscal first quarter, the company generated revenues of $354.6 million, which beat the Zacks Consensus Estimate by 0.06%. The top line improved 7% from the prior-year quarter. As of April 30, 2026, the total number of Health Savings Accounts (HSAs) for which HealthEquity served as a non-bank custodian was 10.6 million, up 8% year over year. HealthEquity reported 909,000 HSAs with investments as of April 30, 2026, up 18% year over year. Total accounts, as of April 30, 2026, were 17.8 million. This uptick included total HSAs and 7.2 million Consumer Direct Benefits (CDBs). Total HSA assets were $37.1 billion at the end of April 30, 2026, up 19% year over year. This included $17.5 billion of HSA cash and $19.6 billion of HSA investments. This figure compares to our fiscal first-quarter HSA cash and HSA investments projection of $17.6 billion and $17.9 billion, respectively. We had projected total HSA assets of $35.5 billion for the fiscal first quarter. Client-held funds, which are deposits held on behalf of HealthEquity’s clients to facilitate the administration of its CDBs and from which the company generates custodial revenues, were $1.0 billion as of April 30, 2026. HealthEquity derives revenues from three sources: Service revenues, Custodial revenues and Interchange revenues. Service revenues totaled $122.9 million in the quarter, up 2.6% year over year. This reflected a higher number of HSAs and invested HSA Assets. This figure compares favorably with our fiscal first-quarter projection of $122 million. Custodial revenues totaled $174.3 million, up 11.4% from the year-ago period. Our projection for the fiscal first-quarter Custodial revenues was $176 million. Interchange revenues totaled $57.4 million, up 5.1% year over year. This figure compares favorably with our fiscal first-quarter projection of $58 million. HealthEquity, Inc. price-consensus-eps-surprise-chart | HealthEquity, Inc. Quote In the quarter under review, HealthEquity’s gross profit rose 14.3% year o...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at West Pharmaceutical Services (NYSE:WST) and the best and worst performers in the drug development inputs & services industry. Companies specializing in drug development inputs and services play a crucial role in the pharmaceutical and biotechnology value chain. Essential support for drug discovery, preclinical testing, and manufacturing means stable demand, as pharmaceutical companies often outsource non-core functions with medium to long-term contracts. However, the business model faces high capital requirements, customer concentration, and vulnerability to shifts in biopharma R&D budgets or regulatory frameworks. Looking ahead, the industry will likely enjoy tailwinds such as increasing investment in biologics, cell and gene therapies, and advancements in precision medicine, which drive demand for sophisticated tools and services. There is a growing trend of outsourcing in drug development for nimbleness and cost efficiency, which benefits the industry. On the flip side, potential headwinds include pricing pressures as efforts to contain healthcare costs are always top of mind. An evolving regulatory backdrop could also slow innovation or client activity. The 8 drug development inputs & services stocks we track reported a satisfactory Q1. As a group, revenues beat analysts’ consensus estimates by 1.6% while next quarter’s revenue guidance was in line. While some drug development inputs & services stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 2.3% since the latest earnings results. Founded in 1923 and serving as a critical link in the pharmaceutical supply chain, West Pharmaceutical Services (NYSE:WST) manufactures specialized packaging, containment systems, and delivery devices for injectable drugs and healthcare products. West Pharmaceutical Services reported revenues of $844.9 million, up 21% year on year. This print exceeded analysts’ expectations by 8.4%. Overall, it was a stunning quarter for the company with a beat of analysts’ EPS and revenue estimates. Eric M. Green, President, Chief Executive Officer and Chair of the Board, commented: "I am pleased to report a very strong start to the year with revenues and adjusted EPS exceed...

NeuroPace NPCE delivered a first-quarter 2026 adjusted loss per share of 13 cents compared with an adjusted loss of 18 cents in the year-ago period. The figure was 31.6% narrower than the Zacks Consensus Estimate. GAAP loss per share for the quarter was 20 cents compared with 21 cents in the year-ago period. NeuroPace registered revenues of $22.1 million in the first quarter, down 2% year over year, reflecting strong RNS System sales of $21.7 million (up 19.5% year over year) alongside $314,000 in service revenues and $0.1 million from DIXI Medical wind-down. The figure surpassed the Zacks Consensus Estimate by 2.07%. Shares of NPCE were up approximately 0.2% during after-market trading following the first-quarter results. The company’s shares have gained 2.3% in the year-to-date period against the industry’s decline of 20.1%. The broader S&P 500 Index has increased 9% in the same time frame. Image Source: Zacks Investment Research In the quarter under review, NeuroPace’s adjusted gross profit increased 18.6% year over year to $18.1 million. Adjusted gross margin contracted 110 basis points (bps) to 82.5%. Sales and marketing expenses increased 5.3% year over year to $11.6 million, research and development expenses decreased 3.4% year over year to $7.2 million and general and administrative expenses increased 19.7% year over year to $4.8 million. Adjusted operating expenses of $21.5 million rose 10.5% year over year. The adjusted operating loss totaled $3.3 million, down from $4.1 million in the prior-year quarter. NeuroPace ended first-quarter 2026 with total cash, cash equivalents and short-term investments of $53.9 million, compared with $61.1 million at the end of fourth-quarter 2025. Cumulative net cash used in operating activities at the end of first-quarter 2026 was $5.9 million compared with $7.5 million a year ago. NeuroPace has raised its outlook for the full year 2026. For 2026, management provided total revenue guidance of $99 million-$101 million (up from $98 million to $100 million previously) on a continuing-operations basis, with RNS growth of 21%-23%, compared to full year 2025. The Zacks Consensus Estimate is pegged at $98.8 million. The adjusted gross margin is expected to be at 81.5%-82.5%, supported by ongoing pricing discipline and manufacturing efficiencies. Adjusted operating expenses are guided to $90 million-$92million, excluding ap...

Doximity, Inc. DOCS delivered adjusted earnings per share (EPS) of 26 cents in the fourth quarter of fiscal 2026, down 31.6% year over year. The figure missed the Zacks Consensus Estimate by 7.1%. GAAP EPS for the quarter was 10 cents, reflecting a downtick of 67.7% from the year-ago figure. Adjusted EPS for fiscal 2026 was $1.52, up 7% year over year. GAAP EPS for fiscal 2026 was 98 cents, down 11.7% year over year. Doximity registered revenues of $145.4 million in the fiscal fourth quarter, up 5% year over year. The figure surpassed the Zacks Consensus Estimate by 1.2%. The revenue growth was driven by stronger spending from existing customers, reflected in a 109% net revenue retention rate and growth in large accounts, with 125 customers contributing over $500,000 in subscription-based revenues and representing 83% of revenues. Total revenues for fiscal 2026 were $644.9 million, up 13% year over year. Following the earnings release, shares of DOCS fell 19.3% in after-hours trading yesterday. The company’s shares have lost 47.2% in the year-to-date period compared with the industry’s decline of 23%. However, the broader S&P 500 Index has increased 8.7% in the same time frame. Image Source: Zacks Investment Research In the quarter under review, Doximity’s adjusted gross profit rose 2.7% year over year to $129.9 million. However, the adjusted gross margin contracted 210 basis points (bps) to 89.3%. Sales and marketing expenses increased 22.1% year over year to $45.9 million, and research and development expenses rose 57.7% year over year to $39.1 million. General and administrative expenses increased 26.7% year over year to $16.1 million. Total operating expenses of $101.1 million rose 34.6% year over year. The adjusted operating profit totaled $63.6 million, reflecting a 6.4% downtick from the prior-year quarter. The adjusted operating margin in the fiscal fourth quarter contracted 530 bps to 43.8%. Doximity exited fourth-quarter fiscal 2026 with cash and cash equivalents of $219.2 million compared with $64.8 million at the fiscal third-quarter end. Cumulative net cash provided by operating activities at the end of fourth-quarter fiscal 2026 was $109.5 million compared with $98.5 million a year ago. Doximity has provided its financial outlook for the fiscal first quarter and the full year of fiscal 2027. For the fiscal first quarter, the company expects rev...

Rigetti Computing RGTI reported first-quarter 2026 adjusted loss per share of 4 cents, narrower than the loss per share of 8 cents in the prior-year quarter. The metric also surpassed the Zacks Consensus Estimate of earnings by 20%. GAAP loss per share in the reported quarter was 6 cents against the earnings per share of 13 cents in the prior-year quarter. Shares of this company gained nearly 8.3% in yesterday’s trading session. The company reported total revenues of $4.4 million, up 198.9% year over year. The top line surpassed the Zacks Consensus Estimate by 35.6%. Rigetti’s first-quarter 2026 revenues were driven primarily by higher sales of its on-premises Novera quantum systems and broader customer adoption across academic, government and research institutions. The commercial rollout of its 108-qubit Cepheus-1-108Q system across major cloud platforms also supported top-line growth. In the quarter under review, RGTI’s gross profit improved 211.8% year over year to $1.4 million. The gross margin expanded 130 basis points to 31.3%. Selling, general and administrative expenses increased 11.4% year over year to $7.4 million. Research and development expenses increased 29.1% year over year to $19.9 million. Total operating expenses of $27.3 million increased 23.8% year over year. Operating loss for the quarter under review totaled $25.9 million compared with $21.6 million in the prior-year quarter. RGTI exited the first quarter of 2026 with cash, cash equivalents and short-term available-for-sale investments of $418.2 million compared with $443.5 million at the end of the fourth quarter of 2025. The company ended the quarter with no debts on its balance sheet. Net cash used in operating activities at the end of the first quarter was $16.2 million compared with $13.7 million a year ago. Rigetti Computing, Inc. price-consensus-eps-surprise-chart | Rigetti Computing, Inc. Quote Rigetti exited first-quarter 2026 with strong results, wherein both earnings and revenues surpassed the Zacks Consensus Estimate. Solid year-over-year revenue growth, driven by the rising adoption of its on-premises quantum systems and broader customer traction across academic, government and commercial markets, was encouraging. The company also benefited from the continued commercialization of its 108-qubit Cepheus-1-108Q platform and maintained a robust liquidity position. However, elev...

AMN Healthcare Services, Inc. AMN delivered adjusted earnings per share (EPS) of $2.10 in the first-quarter 2026, up 367% year over year. The figure surpassed the Zacks Consensus Estimate by 31.3%. GAAP EPS for the quarter was $1.59 against a loss per share of 3 cents in the year-ago period. AMN Healthcare registered revenues of $1.38 billion in the first quarter, up 100% year over year. The figure surpassed the Zacks Consensus Estimate by 11.9%. Shares of this company gained nearly 3.1% in yesterday’s after-hours trading. The company’s shares have rallied 44.8% in the year-to-date period against the industry’s decline of 13.1%. However, the S&P 500 Index has increased 8.5% in the same time frame. Image Source: Zacks Investment Research AMN Healthcare conducts its business via three reportable segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. In the first quarter of 2026, the Nurse and Allied Solutions segment’s revenues totaled $1.13 billion, up 173% year over year. Travel nurse staffing revenues were up 12% year over year, whereas Allied revenues increased 3% year over year. Labor disruption events contributed $722 million in revenues in the quarter. The Zacks Consensus Estimate was pegged at $984 million. The Physician and Leadership Solutions segment’s revenues totaled $163.9 million, down 6% year over year. Locum tenens revenues were $131 million in the quarter, down 7% year over year. Interim leadership revenues were down 4% year over year. Physician and leadership search businesses saw a revenue increase of 4% year over year. The Zacks Consensus Estimate was pegged at $163 million. The Technology and Workforce Solutions segment’s revenues totaled $87.1 million, down 15% year over year. Language interpretation services business revenues came in at $69 million in the quarter, down 8% year over year, while the vendor management systems business saw an 18% year-over-year revenue decline to reach $16 million. The Zacks Consensus Estimate was pegged at $85 million. In the quarter under review, AMN Healthcare’s gross profit increased 86.2% year over year to $368.8 million. The gross margin contracted 190 basis points (bps) to 26.8%. Selling, general & administrative expenses fell 47.8% year over year to $218.4 million. Operating profit totaled $117.2 million, reflecting an increase of 836.8% fro...

McKesson Corporation MCK is scheduled to report fourth-quarter fiscal 2026 results on May 7, after market close. The Zacks Consensus Estimate for sales is pegged at $101.92 billion, implying 12.2% year-over-year growth. The bottom line estimate is pinned at $11.56, suggesting growth of 14.2%. The EPS estimates have remained stable over the past seven days. The company delivered an earnings surprise of 0.32% in the last reported quarter. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 3.60%. McKesson Corporation price-eps-surprise | McKesson Corporation Quote Our proven model does not conclusively predict an earnings beat for McKesson this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below. Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate is -0.07% for MCK. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: The company carries a Zacks Rank #3 at present. McKesson is expected to have delivered another solid quarterly performance in the fiscal fourth quarter, supported by continued momentum across its oncology and multispecialty platform, strength in biopharma services, and resilient pharmaceutical distribution trends. Management highlighted broad-based demand across specialty distribution and stable utilization trends in the prior quarter, while raising full-year adjusted EPS guidance to $38.80-$39.20, implying confidence in sustained operational execution. The North American Pharmaceutical segment likely remained the primary growth engine, benefiting from higher prescription volumes, specialty product distribution strength, and continued GLP-1 demand. GLP-1 distribution revenues rose 26% year over year in the prior quarter to $14 billion, and management suggested that the category continues to expand despite variability in quarterly trends. Specialty distribution growth from health systems and retail national accounts is also expected to have supported segment profitability. Operational efficiency initiatives, including AI-enabled workflow automation and improved inventory management, likely aided margins. However, brand...

Inogen, Inc. INGN incurred an adjusted loss per share of 30 cents for first-quarter 2026, wider than the year-ago period’s adjusted loss of 25 cents per share. The Zacks Consensus Estimate was pinned at a loss of 24 cents per share. GAAP loss per share for the quarter was 26 cents, narrower than the year-earlier loss of 41cents. Inogen registered revenues of $85.1 million for the first quarter, up 3.4% year over year. The figure beat the Zacks Consensus Estimate by 3.3%. At constant exchange rate (CER), total revenues for the reported quarter decreased 1.2% year over year. Per management, the year-over-year uptick in the top line was primarily driven by higher demand for portable oxygen concentrators in international markets, partially offset by lower U.S. sales and U.S. rentals. Shares of this company lost 4.2% in yesterday’s after-market trading. Its shares have gained 6.9% so far this year against the industry’s 15.5% decline. The S&P 500 Index has increased 8.5% in the same time frame. Image Source: Zacks Investment Research In the fourth quarter of 2025, Inogen revised its product revenue classification to offer investors clearer insight into underlying business trends and strategic priorities. The company now reports under three categories — U.S. sales, international sales and U.S. rentals. Total sales were $68.6 million, up 3.4% from the prior-year quarter’s level. U.S. sales amounted to $34.7 million, down 4.8% year over year, while International sales improved 17.8% to $37.7 million. U.S. rental revenues for the reported quarter grossed $12.7 million, down 8% from the year-ago period’s level. In the quarter under review, Inogen’s adjusted gross profit gained 4.1% from the year-ago period to $38.1 million. The adjusted gross margin improved 30 basis points to 44.7%. Sales and marketing expenses increased 3.6% from the year-ago quarter’s figure to $24.6 million. Research and development expenses increased 26.4% year over year to $5.1 million, while general and administrative expenses increased 7.8% to $17.5 million. Adjusted operating expenses were $43 million, up 5.1% year over year. Adjusted operating loss totaled $5 million compared with the prior-year quarter’s loss of $4.4 million. Inogen exited the first quarter of 2026 with cash and cash equivalents of $93.1 million compared with $103.7 million at the end of the fourth quarter of 2025. The comp...

McKesson Corporation MCK reported fourth-quarter fiscal 2026 adjusted earnings per share (EPS) of $11.69, which beat the Zacks Consensus Estimate of $11.56 by 1.1%. The bottom line improved 15.5% on a year-over-year basis. The EPS growth was driven by strong operational improvement across the business, including contributions from acquisitions in the Oncology & Multispecialty segment. GAAP EPS was $13.71 compared with $10.01 in the year-ago quarter. The significant improvement in EPS was due to a pre-tax credit within the North American Pharmaceutical segment related to the Rite Aid bankruptcy. For fiscal 2026, adjusted EPS was up 18.3% to $39.11 while GAAP EPS gained 49.2% to $38.38. Revenues of $96.3 billion missed the Zacks Consensus Estimate by 5.5%. The top line gained 6% year over year, primarily driven by increased prescription volumes from retail national account customers and growth in the distribution of oncology and specialty products, including contributions from the Oncology & Multispecialty segment. These were partially offset by lower contributions from branded pharmaceuticals. Higher contributions from the Prescription Technology Solutions segment also aided the top line. For fiscal 2026, revenues amounted to $403.43 billion, gaining 12.4% year over year. Shares of MCK were down 0.4% in the after-hours trading on May 7, following mixed results. The company’s shares have lost 9.7% so far this year compared with the industry’s 10.4% decline. The S&P 500 Index has increased 8.6% in the same time frame. Image Source: Zacks Investment Research The company started reporting under new reportable segments and organizational structure, effective from the second quarter of fiscal 2026. The current reporting segments are North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions and Medical-Surgical Solutions. Revenues from the North American Pharmaceutical segment totaled $79.12 billion, up 3% year over year. Per management, the upside was primarily driven by increased prescription volumes, including higher volumes from specialty products, partially offset by lower contributions from branded pharmaceuticals. The U.S. Pharmaceutical and Specialty Solutions segment reported an adjusted operating profit of $980 million, up 11% from the prior-year quarter’s level. This was due to growth in the distribution of specialty prod...

DaVita Inc. DVA delivered adjusted earnings per share (EPS) from continuing operations of $2.87 in the first quarter of 2026, up 43.5% year over year. The figure surpassed the Zacks Consensus Estimate by 19.1%. GAAP EPS from continuing operations for the quarter was also $2.87, reflecting an uptick of 43.5% year over year. Revenues of $3.42 billion in the first quarter increased 5.9% year over year. The figure topped the Zacks Consensus Estimate by 3.5%. Revenue per treatment (RPT) in the first quarter of 2026 was $417.6 million, up 4.4% year over year, but down 1.2% sequentially. Per management, the sequential decline was primarily the result of the typical first-quarter headwind from patient-pay responsibility. Shares of this company gained nearly 6.1% in today’s pre-market trading. DaVita generates revenues via two sources — Dialysis patient service revenues and Other revenues. The dialysis patient service revenues were $3.27 billion, up 5.5% year over year. Other revenues were $142.8 million, up 18.4% from the year-ago quarter’s figure. Per management, the total U.S. dialysis treatments for the first quarter were 7,029,525 or 91,650 per day, on average. This represents a per-day increase of 0.05% on a sequential basis. Normalized non-acquired treatment increased 0.1% year over year in the first quarter of 2026. As of March 31, 2026, DaVita provided dialysis services to around 296,300 patients at 3,262 outpatient dialysis centers, of which 2,666 were U.S. centers while 596 were located across 14 other countries. As of March 31, 2026, DVA had approximately 62,600 patients in risk-based integrated care arrangements in its Integrated Kidney Care business, representing $5.4 billion in annualized medical spend. The company also had an additional 6,300 patients in other integrated care arrangements. DaVita Inc. price-consensus-eps-surprise-chart | DaVita Inc. Quote In the quarter under review, DaVita’s gross profit increased 9.1% year over year to $1.07 billion. The gross margin expanded 90 basis points (bps) to 31.4%. General & administrative expenses climbed 12.8% year over year to $421.9 million. Adjusted operating profit totaled $651.4 million, reflecting a 6.8% increase from the prior-year quarter’s level. Adjusted operating margin in the first quarter expanded 15 bps to 19.1%. DaVita exited first-quarter 2026 with cash and cash equivalents and short-term...

Avanos Medical, Inc. AVNS reported first-quarter 2026 adjusted earnings per share (EPS) from continuing operations of 22 cents, down 15.4% year over year. The bottom line missed the Zacks Consensus Estimate of 23 cents. GAAP EPS from continuing operations in the quarter under review was 11 cents compared with the year-ago period’s EPS of 14 cents. Revenues totaled $182.2 million in the reported quarter, up 8.8% year over year. The metric beat the Zacks Consensus Estimate by 7.6%. The top line gained from higher volume across its Specialty Nutrition Systems (SNS) segments. Shares of the company gained nearly 0.1% during after-market trading following the first-quarter results on Monday. The company’s shares have jumped 120.1% in the year-to-date period against the industry’s decline of 15.7%. The broader S&P 500 Index has increased 6.8% in the same time frame. Image Source: Zacks Investment Research Avanos generates revenues from three segments: SNS, PM&R, and Corporate and Other. The SNS segment’s revenues in the first quarter of 2026 totaled $124 million, up 22.7% year over year. This figure beat our first-quarter projection of $107 million. The segment recorded 19% volume growth, driven by continued strong demand across both our enteral feeding and neonate solutions. The Enteral feeding unit’s revenues totaled $84.6 million for the first quarter of 2026 (up 13.6% year over year), while the Neonate solutions unit’s revenues amounted to $39.4 million (up 48.1% year over year). The PM&R segment’s revenues totaled $56.3 million, up 0.2% year over year. However, the figure missed our projection of $62 million. The PM&R segment’s volume growth in Radio Frequency Ablation (RFA) was partially offset by reduced volume in surgical pain and recovery product lines. Net sales of RFA products grew 8.8% year over year to $34.5 million, reflecting momentum in RFA generator sales. Net sales in the surgical pain and recovery unit declined 11% year over year to $21.8 million. The Corporate and Other segment’s revenues totaled $1.9 million, down 81.4% year over year. In the quarter under review, Avanos’ adjusted gross profit increased 2.4% year over year to $97.3 million. The adjusted gross margin contracted 330 basis points (bps) to 53.4%. We had projected a gross margin of 54.2% for the first quarter. Selling and general expenses increased 2.6% year over year to $77.7 milli...

Clover Health Investments, Corp. CLOV delivered adjusted earnings per share (EPS) of 7 cents in first-quarter 2026, higher than the year-ago period’s level of 5 cents. The bottom line met with the Zacks Consensus Estimate. The company reported a GAAP EPS of 5 cents per share from continuing operations, compared with breakeven earnings in the year-ago period. Clover Health registered total revenues of $749.2 million, up 62.1% year over year. The figure beat the Zacks Consensus Estimate by 5.9%. The top line gained from robust Insurance revenues. Clover Health Investments, Corp. price-consensus-eps-surprise-chart | Clover Health Investments, Corp. Quote The company derives its revenues from two primary business segments: Insurance and Other income. Insurance revenues in the first quarter totaled $744.2 million, up 62.9% year over year. According to management, this growth was primarily driven by a 51.6% increase in Medicare Advantage membership, strong member retention, clinical initiatives and the impact of Clover Assistant-powered care platform. Within CLOV’s Insurance segment, the Insurance Benefit Expense Ratio (BER) was 86.5%, reflecting a year-over-year increase from 86.1% in the year-ago quarter. Insurance BER rose due to new member dilution and incremental quality investments. Other income was $5 million, down 7.8% from the prior-year level. In the quarter under review, Clover Health’s net medical claims increased 66.8% year over year to $589.6 million. Salaries and benefits expenses decreased 3.3% to $57.1 million, while general and administrative expenses rose 47.3% to $74.6 million. Total operating expenses of $721.9 million increased 55.7% on a year-over-year basis. Total operating income was $27.3 million against the prior-year quarter’s operating loss of $1.3 million. The company exited first-quarter 2026 with cash and cash equivalents of $173.3 million compared with $78.3 million at the end of 2025. Net cash provided by operating activities from continuing operations at the end of first-quarter 2026 was $107.9 million against $16.3 million of net cash used in operating activities from continuing operations in the year-ago period. Clover Health provided its revenue outlook for 2026. For 2026, total revenues are estimated to be in the range of $2.81-$2.92 billion, suggesting 49% year-over-year growth at the midpoint. The Zacks Consensus Estimate i...